Open AccessOral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review
Author(s) -
JuanFrancisco PeñaCardelles,
Ángel-Orión Salgado-Peralvo,
Pablo Garrido-Martínez,
José Luis Cebrián Carretero,
José Juan PozoKreilinger,
José Ernesto Moro-Rodríguez
Publication year - 2021
Publication title -
medicina oral, patología oral y cirugía bucal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.644
H-Index - 56
eISSN - 1698-6946
pISSN - 1698-4447
DOI - 10.4317/medoral.24353
Subject(s) - mucositis , medicine , oral cancers , immunotherapy , oral immunotherapy , immune system , nivolumab , cancer , oncology , immunology , chemotherapy
Oral mucositis (OM) is a painful lesion that takes place in the mucosa of the oral cavity, usually its etiology is associated with drug therapies in cancer patients. It is presented as well-defined ulcers whose painful symptomatology sometimes implies the suspension of oncological treatment or parenteral feeding, being therefore an important adverse effect, marking the evolution of these types of therapies against cancer. The present work aim is to know the prevalence of oral mucositis in oral cancer immunotherapy compared to its prevalence in standard therapy.